CIDeRGeneral Information:
| Id: | 7,848 (click here to show other Interactions for entry) |
| Diseases: |
Alzheimer disease
- [OMIM]
|
| Homo sapiens | |
| fresh frozen brain tissue blocks of middle frontal gyrus (MFG), middle temporal gyrus (MTG), and cerebellum were obtained from normal subjects and cases of definite AD diagnosed according to CERAD criteria | |
| article | |
| Reference: | Bandaru VV et al.(2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimers but not normal brain Neurobiol. Aging 30: 591-599 [PMID: 17888544] |
Interaction Information:
| Comment | The epsilon 4 allele of ApoE is associated with an earlier onset and faster progression of Alzheimer's disease in patients with the familial form of this neurodegenerative condition. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. |
|
Formal Description Interaction-ID: 78037 |
|
| Comment | The epsilon 4 allele of ApoE is associated with an earlier onset and faster progression of Alzheimer's disease in patients with the familial form of this neurodegenerative condition. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. |
|
Formal Description Interaction-ID: 78301 |
gene/protein mutant decreases_activity of process |
| Comment | The epsilon 4 allele of ApoE is associated with an earlier onset and faster progression of Alzheimer's disease in patients with the familial form of this neurodegenerative condition. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. |
|
Formal Description Interaction-ID: 78302 |
gene/protein mutant decreases_activity of process |
| Comment | In the MFG grey matter of AD patients with an ApoE4 genotype, there were increased levels of cholesterol, and the cholesterol esters C16:0, and C18:1 (range 2.6- to 3.4-fold). |
|
Formal Description Interaction-ID: 78329 |
gene/protein mutant increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | In the MFG grey matter, there were significant decreases of sphingomyelin C22:0 (12.5-fold), and C24:0 (6.2-fold), and significant increases of ceramide C18:0 (2.0-fold) and C24:1 (1.8-fold) in ApoE4 compared with ApoE3 AD brain. |
|
Formal Description Interaction-ID: 78335 |
gene/protein mutant decreases_quantity of drug/chemical compound SM C22:0 |
| Comment | In the MFG white matter, while there were no significant differences in sphingomeylin, there were significant differences in ceramide C22:0 (2.6-fold increase), C24:0 (1.2-fold decrease), and sulfatide (1.7-fold increase), in ApoE4 vs. ApoE3 brain. |
|
Formal Description Interaction-ID: 78337 |
gene/protein mutant increases_quantity of drug/chemical compound Ceramide C22:0 |
| Comment | In the MFG grey matter there was a significant increase in the lysine adduct of 4-HNE (4.9-fold) and, no significant difference in MFG white matter content of ApoE4 compared with ApoE3 AD brain. |
|
Formal Description Interaction-ID: 78338 |
gene/protein mutant increases_quantity of drug/chemical compound |
| Comment | Ceramides C18:0, C24:1 and sulfatide were increased in the MFG (middle frontal gyrus) grey matter of ApoE4 AD patients (1.8- to 2.0-fold). |
|
Formal Description Interaction-ID: 78339 |
gene/protein mutant increases_quantity of drug/chemical compound Ceramide C18:0 |
| Comment | In the MTG (middle temporal gyrus) grey matter, only the cholesterol ester C18:1 was elevated (2.4-fold) in AD patients expressing ApoE4 compared with AD patients expressing ApoE3. |
|
Formal Description Interaction-ID: 78369 |
gene/protein mutant increases_quantity of drug/chemical compound Cholesterol ester C18:1 |
| Comment | In the MFG grey matter of AD patients with an ApoE4 genotype, there were increased levels of cholesterol, and the cholesterol esters C16:0, and C18:1 (range 2.6- to 3.4-fold). |
|
Formal Description Interaction-ID: 78370 |
gene/protein mutant increases_quantity of drug/chemical compound Cholesterol ester C16:0 |
| Comment | In the MFG grey matter of AD patients with an ApoE4 genotype, there were increased levels of cholesterol, and the cholesterol esters C16:0, and C18:1 (range 2.6- to 3.4-fold). |
|
Formal Description Interaction-ID: 78371 |
gene/protein mutant increases_quantity of drug/chemical compound Cholesterol ester C18:1 |
| Comment | In the MFG grey matter, there were significant decreases of sphingomyelin C22:0 (12.5-fold), and C24:0 (6.2-fold), and significant increases of ceramide C18:0 (2.0-fold) and C24:1 (1.8-fold) in ApoE4 compared with ApoE3 AD brain. |
|
Formal Description Interaction-ID: 78372 |
gene/protein mutant decreases_quantity of drug/chemical compound SM C24:0 |
| Comment | In the MFG white matter, while there were no significant differences in sphingomeylin, there were significant differences in ceramide C22:0 (2.6-fold increase), C24:0 (1.2-fold decrease), and sulfatide (1.7-fold increase), in ApoE4 vs. ApoE3 brain. |
|
Formal Description Interaction-ID: 78373 |
gene/protein mutant decreases_quantity of drug/chemical compound Ceramide C24:0 |
| Comment | In the MFG white matter, while there were no significant differences in sphingomeylin, there were significant differences in ceramide C22:0 (2.6-fold increase), C24:0 (1.2-fold decrease), and sulfatide (1.7-fold increase), in ApoE4 vs. ApoE3 brain. |
|
Formal Description Interaction-ID: 78374 |
gene/protein mutant increases_quantity of drug/chemical compound |
| Comment | Ceramides C18:0, C24:1 and sulfatide were increased in the MFG (middle frontal gyrus) grey matter of ApoE4 AD patients (1.8- to 2.0-fold). |
|
Formal Description Interaction-ID: 78377 |
gene/protein mutant increases_quantity of drug/chemical compound Ceramide C24:1 |
| Comment | Ceramides C18:0, C24:1 and sulfatide were increased in the MFG (middle frontal gyrus) grey matter of ApoE4 AD patients (1.8- to 2.0-fold). |
|
Formal Description Interaction-ID: 78378 |
gene/protein mutant increases_quantity of drug/chemical compound |